Casdin, Meister disclose sizable GeneDx (WGS) ownership positions
Eli Casdin and Keith Meister have disclosed updated significant ownership positions in GeneDx Holdings Corp. (WGS) through a Schedule 13D/A filing. Casdin reports beneficial ownership of 13.7% and Meister 17.9% of GeneDx's Class A common stock, including shares held through various investment entities, warrants, and restricted stock units. This filing highlights substantial institutional involvement and the specifics of their holdings, calculated based on 29,688,027 shares outstanding as of May 1, 2026.
Casdin-linked funds add 500K GeneDx (WGS) shares in open-market buys
Investment entities associated with Casdin Capital, including Casdin Partners Master Fund, L.P., made open-market purchases of 500,000 shares of GeneDx Holdings Corp. (WGS) Class A Common Stock between May 18-20, 2026. These transactions, valued at over $21 million, increased the fund's indirect holdings to 3,507,164 shares, with Eli Casdin also holding direct and other indirect shares. The weighted average purchase prices were in the low-to-mid $40 range, indicating a positive sentiment from the insider buys.
Casdin Partners master fund buys $21.5 million in GeneDx stock
Casdin Partners Master Fund, L.P., an entity linked to GeneDx Holdings Corp. director Eli Casdin, recently acquired approximately 500,000 shares of GeneDx stock across three transactions for a total of $21.5 million. These purchases occurred between May 18 and May 20, 2026, amidst significant stock volatility and follows a 66% decline over the past six months. Despite recent earnings missing analyst expectations and revised guidance, the fund's continued investment highlights a notable insider transaction.
Corvex management, director Keith Meister buy $13.7m GeneDx stock
Corvex Management and director Keith Meister collectively purchased $13.7 million worth of GeneDx Holdings Corp. (NASDAQ:WGS) Class A Common Stock between May 13 and May 15, 2026. These insider transactions occurred while the stock was trading near its 52-week low, following a significant 68% decline over the past six months. This comes after GeneDx reported lower-than-expected Q1 2026 earnings and revenue, leading to reduced price targets from analysts who nonetheless maintained Buy ratings.
Corvex-linked funds boost GeneDx (WGS) stake with 351K-share open-market buy
Investment funds advised by Corvex Management LP significantly increased their stake in GeneDx Holdings Corp. (WGS) by purchasing 351,273 Class A Common Stock shares through open-market transactions between May 13 and May 15, 2026. These purchases were made at weighted average prices ranging from $37.78 to $40.60 per share, bringing the total direct holdings of Corvex-advised funds to 4,784,570 shares. Keith A. Meister, a director and 10% owner, is associated with these holdings and also directly holds shares from vested restricted stock units.
Casdin and Meister report 12% and 17.9% GeneDx (WGS) stakes
Eli Casdin and Keith Meister have updated their beneficial ownership stakes in GeneDx Holdings Corp. (WGS) through a Schedule 13D/A filing. Casdin now beneficially owns 12% of the Class A common stock, totaling 3,599,671 Shares, while Meister holds 17.9%, amounting to 5,356,767 Shares. These holdings include shares held through various entities, private placement warrants, and equity awards for board service, with ownership percentages based on 29,688,027 Shares outstanding as of May 1, 2026.
WGS Investor Alert: Levi & Korsinsky Investigates GeneDx Holdings Corp. (WGS) for Potential Securities Fraud
Levi & Korsinsky is investigating GeneDx Holdings Corp. (WGS) for potential securities fraud after a significant drop in share value following its Q1 2026 earnings report. The company's CFO had promised quarterly profitability and reaffirmed strong full-year guidance weeks before reporting an $8.2 million loss and cutting full-year revenue projections by approximately 12%. Shareholders who suffered losses are encouraged to contact the firm for a legal rights evaluation.
GeneDx Holdings Corp. (NASDAQ:WGS) Analysts Just Slashed This Year's Revenue Estimates By 12%
Analysts have significantly cut their revenue forecasts for GeneDx Holdings Corp. (NASDAQ:WGS) for the current year by 12%, now expecting US$486m compared to previous estimates of US$550m. Despite the downgrade, the company's stock rose 14% in the past week, and analysts still anticipate GeneDx Holdings to grow faster than the broader industry. The price target was also slashed by 43% to US$77.00, indicating increased pessimism regarding its intrinsic value.
Monday’s insider activity: GeneDx director buys $46.8M in stock By Investing.com
This article details significant insider trading activity on Monday, May 11, 2026, focusing on major buys and sells in US-listed stocks. GeneDx Holdings Corp. saw a director acquire $46.8 million in stock, while Life Time Group Holdings, Inc. experienced large insider selling totaling over $157 million. The report highlights several companies where insiders are either increasing their stake, suggesting confidence, or divesting, often when stocks are near highs or deemed overvalued by InvestingPro analysis.
GeneDx holdings: director Keith Meister-affiliated entities buy $46.8m By Investing.com
Keith A. Meister, a director at GeneDx Holdings Corp. and affiliated with Corvex Management LP, acquired approximately $46.8 million worth of the company’s Class A Common Stock between May 7 and May 11, 2026. These purchases, made at prices ranging from $35.46 to $41.15 per share, come after a significant 71% stock decline over six months. Despite recent disappointing Q1 2026 earnings and lowered price targets from analysts, the stock is considered undervalued with substantial upside potential, according to InvestingPro analysis.
GeneDx holdings: director Keith Meister-affiliated entities buy $46.8m
Director Keith A. Meister and entities affiliated with Corvex Management LP purchased approximately $46.8 million worth of GeneDx Holdings Corp. (NASDAQ:WGS) Class A Common Stock between May 7 and May 11, 2026. This insider buying occurred while the stock is trading near the lower end of Meister's purchase range and after a 71% decline over the past six months, with analysts suggesting significant upside potential. These purchases increased Corvex-advised funds' indirect holdings to 4,433,297 shares, alongside Meister's direct and other indirect holdings.
Corvex funds linked to Keith Meister buy 1.2M GeneDx (WGS) shares
Funds advised by Corvex Management LP, linked to director Keith A. Meister, purchased 1,205,147 shares of GeneDx Holdings Corp. (WGS) Class A Common Stock between May 7 and May 11, 2026. These open-market transactions occurred at weighted average prices ranging from the mid-$30s to low-$40s per share, increasing Corvex's direct holdings to 4,433,297 shares. The filing also detailed other GeneDx holdings related to Mr. Meister, including shares held by CMLS Holdings LLC and those from vested restricted stock units.
[SCHEDULE 13D/A] GeneDx Holdings Corp. Amended Major Shareholder Report
This report details an amended Schedule 13D filing for GeneDx Holdings Corp. by major shareholders Eli Casdin and Keith Meister. It updates their beneficial ownership percentages, noting Meister's 16.7% and Casdin's 12.0% stake based on 29,688,027 shares outstanding as of May 1, 2026. The amendment also discloses new cash-settled swaps entered into by Casdin Partners Master Fund, LP, providing economic exposure to an additional 850,000 shares without conferring voting rights.
Casdin fund boosts GeneDx (WGS) exposure via 850K share swaps
Casdin Partners Master Fund, L.P. has increased its economic exposure to GeneDx Holdings Corp. (WGS) through cash-settled swap agreements referencing 850,000 notional shares. These transactions occurred on May 7, 8, and 11, 2026, at various prices. While providing economic results similar to ownership, these swaps do not grant Casdin voting or disposition power over GeneDx shares, and the beneficial ownership is indirect.
GENEDX INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is
Bragar Eagel & Squire, P.C., a stockholder rights law firm, is investigating GeneDx Holdings Corp. (NASDAQ:WGS) after the company announced lower-than-expected financial results and reduced its 2026 revenue guidance. This investigation follows a significant drop in GeneDx's stock price after reporting a $57.5 million loss from operations and a $31.3 million write-down. The firm is encouraging GeneDx stockholders who experienced losses to contact them to discuss their legal options regarding potential violations of federal securities laws.
If AI Reshapes Healthcare, These Three Stocks Could Lead
This article identifies three stocks – GeneDx Holdings (WGS), Medtronic (MDT), and Stryker (SYK) – as potential leaders in healthcare as artificial intelligence continues to reshape the industry. It highlights their current market position, AI-driven initiatives in diagnostics, treatment, and research, and discusses financial outlooks, risks, and opportunities for each company. The piece emphasizes long-term structural themes over short-term macroeconomic swings for investors interested in AI's role in healthcare.
GeneDx Holdings (WGS) Returns To US$17.7 Million Quarterly Loss Challenging Bullish Profitability Narrative
GeneDx Holdings (WGS) reported a widened quarterly loss of US$17.7 million in Q4 2025, challenging the bullish narrative of a swift path to profitability. The company's financial performance has seen significant swings, moving from a profit in Q2 2025 back to losses, despite growing revenues. While bulls point to forecasted growth and long-term profitability, bears highlight the company's premium P/S ratio despite ongoing losses and the potential for setbacks in its growth trajectory.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS
Pomerantz LLP is investigating GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of investors for potential securities fraud or unlawful business practices. This investigation follows GeneDx's May 4, 2026, financial report, which revealed lower-than-expected revenue and a significant reduction in full-year 2026 guidance, leading to a nearly 50% stock price drop. Investors impacted by this decline are encouraged to contact Pomerantz LLP.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS
Pomerantz LLP has announced an investigation into GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of investors, following a significant drop in its stock price. The investigation concerns potential securities fraud or unlawful business practices after GeneDx reported lower-than-expected Q1 2026 financial results and significantly reduced its full-year revenue guidance. The company’s stock fell 49.20% after disclosing issues with reimbursement rates and non-core business performance.
INVESTOR ALERT: Investigation of GeneDx Holdings Corp. (WGS) announced by Holzer & Holzer, LLC
Holzer & Holzer, LLC announced an investigation into GeneDx Holdings Corp. (WGS) after the company reported lower-than-expected Q1 2026 revenue and revised guidance, causing a stock drop. The firm is encouraging investors who suffered losses to contact them to discuss their legal rights regarding potential violations of federal securities laws.
Why Is GeneDx Stock Surging Thursday?
GeneDx Holdings Corp. (NASDAQ: WGS) stock surged on Thursday due to bargain hunting after a significant post-earnings sell-off. Despite cutting full-year revenue guidance and missing Q1 estimates, investors were emboldened by ARK Investment Management's share purchases and strong operational metrics like 34% year-over-year growth in exome and genome testing volume. The company also reported expanding Medicaid coverage and new partnerships, though technical analysis still points to a bearish long-term trend.
Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against GeneDx Holdings Corp.
Ademi LLP has launched an investigation into GeneDx Holdings Corp. (Nasdaq: WGS) for potential securities fraud. The investigation stems from allegations that GeneDx may have made inaccurate statements regarding its financial statements, business operations, and prospects. Shareholders are invited to join the investigation.
GeneDx Holdings Corp. (WGS) Stock Falls on Q1 2026 Earnings
GeneDx Holdings Corp. (WGS) reported its Q1 2026 earnings, showing revenue of $102.3 million, missing analyst estimates, and a significant net loss. Following the earnings release, the company's stock fell by 32.95%. The article also details recent insider trading activity, institutional investor movements, and analyst ratings and price targets for WGS.
GeneDx Holdings (WGS) grows revenue but books $63M loss on impairments
GeneDx Holdings Corp. (WGS) reported strong revenue growth in Q1 2026, with total revenue increasing 17% to $102.3 million driven by an 18% rise in diagnostic test revenue and a 34% increase in whole exome and genome volumes. However, the company's net loss widened significantly to $63.3 million, primarily due to $31.3 million in non-cash impairment charges related to its Fabric Genomics unit and a $6.6 million loss on debt extinguishment. Despite the widening loss, GeneDx secured a new $100 million term loan from Blackstone, which helped bolster its cash position to $170.7 million after repaying previous debts.
Do You Believe in GeneDx Holdings Corp.’s (WGS) Durable Competitive Moat?
Fred Alger Management's Alger Small Cap Focus Fund highlighted GeneDx Holdings Corp. (WGS) in its Q1 2026 investor letter, noting its strong competitive moat due to its comprehensive genetic data database in pediatric rare disease diagnostics. Despite underperforming the Russell 2000 Growth Index in Q1 2026, the fund believes in GeneDx's established market access, although concerns exist regarding competition and revenue upside. The article also mentions GeneDx is not among the top 40 most popular hedge fund stocks heading into 2026, with greater promise seen in some AI stocks.
GeneDx CFO Kevin Feeley sells $25,555 in shares By Investing.com
GeneDx Holdings Corp.'s CFO, Kevin Feeley, sold 392 shares of Class A Common Stock for $25,555 to cover tax withholding obligations associated with restricted stock units (RSUs). Following the transaction, Feeley directly holds 34,942 shares and has beneficial ownership of additional RSUs and stock options. The company (NASDAQ:WGS) faces competitive challenges despite positive analyst ratings and significant market potential.
GeneDx CFO Kevin Feeley sells $25,555 in shares By Investing.com
GeneDx (NASDAQ:WGS) CFO Kevin Feeley sold 392 shares of Class A Common Stock for $25,555 to cover tax obligations from RSU vesting. This was not a discretionary sale, and Feeley also acquired 754 shares through RSU settlement. The stock has dropped 8% recently, but InvestingPro analysis suggests it remains undervalued.
GeneDx CFO Kevin Feeley sells $25,555 in shares
GeneDx CFO Kevin Feeley sold 392 shares of Class A Common Stock for $25,555 to cover tax withholding obligations associated with vested restricted stock units (RSUs). This transaction was not discretionary and occurred while the stock was trading near $65.38. Feeley now directly holds 34,942 shares and beneficially owns additional RSUs and stock options.
GeneDx (WGS) CEO sells 2,172 shares in tax-related RSU transaction
GeneDx Holdings Corp. CEO Katherine Stueland reported a routine equity compensation activity involving the vesting of 3,874 restricted stock units (RSUs) into Class A Common Stock on April 29, 2026. To cover tax withholding obligations associated with this RSU vesting, she sold 2,172 shares of Class A Common Stock at prices around $64-$65 per share. These sales were classified as "sell to cover" transactions and are not considered discretionary.
GeneDx (WGS) CFO sells small stake to cover RSU taxes
GeneDx Holdings Corp.'s CFO, Kevin Feeley, reported routine equity compensation activity where 754 restricted stock units converted into Class A Common Stock. He subsequently sold 392 shares in a non-discretionary "sell to cover" transaction to fulfill tax withholding obligations. After these transactions, Feeley beneficially owned 34,942 shares of Class A Common Stock, along with contingent rights to receive up to 92,419 additional shares via RSUs and options for 25,906 shares.
[DEF 14A] GeneDx Holdings Corp. Definitive Proxy Statement
GeneDx Holdings Corp. has issued its definitive proxy statement (DEF 14A) for its 2026 virtual annual meeting on June 18, 2026. Stockholders will vote on the election of one Class II director, the ratification of Ernst & Young LLP as auditor, non-binding advisory approval of executive compensation, and the frequency of future say-on-pay votes. The proxy statement details the company's strong 2025 financial performance, including significant revenue growth and adjusted net income, and outlines the executive compensation philosophy which emphasizes a pay-for-performance culture through a mix of base salary, annual cash incentives, and long-term equity incentives, including performance-based restricted stock units (PRSUs).
WGS (NASDAQ: WGS) affiliate sales reported in Form 144; multiple 2026 trades listed
A recent Form 144 filing for GeneDx Holdings Corp. (NASDAQ: WGS) indicates multiple proposed sales of Class A common stock by affiliate Katherine Stueland during 2026. The filing details several sales derived from Restricted Stock Units, along with the individual quantities sold and Stueland's remaining holdings after each transaction. These are routine disclosures of equity compensation dispositions rather than corporate actions.
Insider sells Class A stock at WGS (NASDAQ: WGS) — multiple lots reported
An insider at WGS (NASDAQ: WGS) has filed a Form 144, indicating proposed dispositions of Class A Common Stock. The filing details multiple sales reported in early 2026, totaling over 22,000 shares across several dates, originating from restricted stock units acquired between 2022 and 2023. Morgan Stanley Smith Barney is listed as the broker and NASDAQ as the market for these transactions.
Are Institutional Outflows Quietly Rewriting GeneDx (WGS)’s Genomics‑and‑AI Investment Story?
GeneDx Holdings (WGS) is experiencing weakening sentiment due to institutional outflows and bearish technical signals, despite a core investment narrative around genomics adoption and AI capabilities. While a new $100 million loan from Blackstone provides liquidity, it also increases leverage, making the company more sensitive to slowdowns. Analysts show a wide range of future projections for the company, highlighting diverse investor perspectives on its potential.
GeneDx holdings CFO Feeley sells $557k in shares
GeneDx Holdings Corp's CFO Kevin Feeley sold 7,718 shares for approximately $557,051, while also acquiring 16,250 shares through restricted stock unit exercise. These transactions follow a 17% stock decline over the past week. The company recently reported a 27% increase in fourth-quarter revenue, with analysts maintaining positive ratings and price targets despite competitive introductions in the market.
WGSWW SEC Filings - GeneDx Holdings Corp 10-K, 10-Q, 8-K Forms
This page provides access to GeneDx Holdings SEC filings (WGSWW), including 10-K, 10-Q, 8-K, and insider trading forms. Each filing includes AI-powered summaries to help investors understand key points regarding warrant terms, governance changes, and compensation policies. The platform ensures real-time updates from the SEC’s EDGAR system, making it a comprehensive resource for regulatory disclosures and corporate events.
GeneDx (WGS) CEO exercises 80K RSUs, sells 47K shares for taxes
GeneDx Holdings Corp. CEO Katherine Stueland exercised 80,000 restricted stock units (RSUs) and subsequently sold 46,933 shares to cover tax withholding obligations. These "sell to cover" transactions were non-discretionary and executed at weighted average prices between $60.93 and $65.61 per share. After these transactions, the CEO beneficially owns 91,514 shares of Class A common stock, along with additional RSUs and stock options.
GeneDx (WGS) CFO exercises 16,250 RSUs, sells shares for taxes
GeneDx Holdings Corp.'s CFO, Kevin Feeley, exercised 16,250 restricted stock units (RSUs) and subsequently sold 8,818 Class A Common Stock shares. These sales, conducted at weighted average prices between $60s and $65s per share, were explicitly for covering tax withholding obligations associated with the RSU vesting, categorized as a "sell to cover" transaction rather than a discretionary trade. Following these transactions, Feeley beneficially owns 34,580 Class A Common Stock shares, with additional contingent rights to 93,173 RSU shares and options for 25,906 shares.
GeneDx holdings CFO Feeley sells $557k in shares
GeneDx Holdings CFO Kevin Feeley sold 7,718 shares of Class A Common Stock for approximately $557,051 on March 26, 2026, though he also acquired 16,250 shares through restricted stock unit exercises at $0. This comes as the stock has fallen 17% in the past week, yet analysts maintain Buy ratings with high price targets due to strong Q4 revenue and positive growth outlook, despite new competition.
Can GeneDx (WGS) Turn Cost-Saving Genomics Into Durable Reimbursement Strength?
GeneDx Holdings is gaining positive analyst attention after data presented at the ACMG Annual Meeting showed its genomic tests can reduce healthcare costs and resource use, particularly appealing to payers. While this strengthens the company's case for reimbursement expansion, investors need to be aware of potential risks related to shifts in reimbursement policies or pricing pressures that could impact future value capture despite a recent $100 million term loan from Blackstone. The company projects significant revenue and earnings growth by 2028, leading to a substantial upside in its fair value estimates.
GeneDx CFO Feeley sells $438k in shares after option exercise
GeneDx CFO Kevin Feeley sold 5,706 shares of Class A Common Stock for approximately $438,202 after exercising options. The sale occurred after the stock declined 15% in the past week and remains 56% below its 52-week high. Despite the sale, Feeley retains a significant number of shares and rights to acquire more, while InvestingPro analysis suggests the stock is undervalued with "GOOD" financial health.
GeneDx Holdings Corp. CEO Katherine Stueland Sells Shares to Cover Tax Obligations
GeneDx Holdings Corp. CEO Katherine Stueland sold 17,179 shares of Class A Common Stock on March 16, 2026, to cover tax withholding obligations from RSU vesting. The sales totaled $1,319,290 at weighted average prices between $76.3492 and $77.9354. Following these transactions, Ms. Stueland directly owns 58,447 shares in the company.
GeneDx (WGS) CEO exercises RSUs, sells 17,179 shares to cover taxes
GeneDx Holdings Corp.'s CEO, Katherine Stueland, exercised restricted stock units (RSUs) covering 30,671 shares. To cover tax withholding obligations from these vestings, she sold 17,179 shares in non-discretionary open-market transactions at prices ranging from $75.74 to $78.16 per share. Following these transactions, she still directly owned 58,447 shares and held RSUs and options for a substantial number of additional shares.
GeneDx (WGS) CFO sells shares to cover RSU tax obligations
GeneDx Holdings Corp.'s CFO, Kevin Feeley, reported exercising restricted stock units (RSUs) obtaining 11,012 shares and subsequently selling 5,706 shares of Class A Common Stock. These sales were non-discretionary and exclusively for covering tax withholding obligations associated with the RSU vesting. Following these transactions, Feeley beneficially owns 27,148 shares of Class A Common Stock, with additional RSUs and options outstanding.
WGS SEC Filings - GeneDx Holdings Corp 10-K, 10-Q, 8-K Forms
This page provides access to GeneDx Holdings Corp. (WGS) SEC filings, including 10-K, 10-Q, and 8-K reports, as well as insider trading forms. It highlights recent insider trading activities where directors acquired Class A Common Stock and RSUs, detailing their increased stakes in the company. The platform also offers AI-powered summaries and real-time updates for these regulatory documents.
GeneDx CEO Stueland sells $1.32 million in WGS stock
GeneDx Holdings Corp CEO Katherine Stueland sold 17,179 shares of Class A Common Stock for approximately $1.32 million to cover tax withholding obligations. This sale was not a discretionary transaction. Stueland also exercised options for 30,671 shares and continues to hold a significant number of shares, RSUs, and options. The stock is currently trading down, but analysts remain optimistic with price targets ranging from $130 to $177.
GeneDx (WGS) CEO exercises RSUs, sells shares only to cover taxes
GeneDx Holdings Corp. CEO Katherine Stueland exercised restricted stock units (RSUs) into 6,546 shares of Class A Common Stock. She then sold 3,678 of these shares at a weighted average price of $86.748 per share, explicitly stating this was a "sell to cover" transaction to meet tax withholding obligations and not a discretionary sale. Following these transactions, Stueland directly holds 44,955 shares of Class A Common Stock and retains unvested awards of 445,366 RSUs and options for 107,610 shares, which vest over time.
Corvex management buys GeneDx (WGS) shares worth $13.4 million By Investing.com
Corvex Management LP, including director Keith A. Meister, recently purchased $13.4 million worth of GeneDx Holdings Corp. (NASDAQ:WGS) Class A Common Stock on March 3 and March 5, 2026, despite a 38% stock decline over six months. Analysts maintain optimism with price targets ranging from $130 to $177, though the company reported mixed Q4 results, exceeding revenue but missing earnings expectations. BTIG, Canaccord Genuity, and TD Cowen have reiterated Buy ratings, adjusting price targets based on growth outlook and genetic testing prospects.
GeneDx Holdings (WGS) CFO exercises RSUs and sells shares to cover taxes
GeneDx Holdings Corp. CFO Kevin Feeley exercised restricted stock units (RSUs) for 2,462 shares and subsequently sold 1,280 shares at a weighted average price of $86.754 to cover tax withholding obligations. This "sell to cover" transaction was not a discretionary trade. After these transactions, Feeley directly holds 21,842 shares of Class A common stock and retains RSUs for an additional 120,435 shares and options for 25,906 shares.
GeneDx (WGS) CFO Kevin Feeley acquires 1,986 shares from issuer
GeneDx Holdings Corp. CFO Kevin Feeley acquired 1,986 shares of Class A common stock directly from the company on March 6, 2026, at a price of $88.11 per share. This transaction was exempt under Rule 16b-3(d) and increased his direct ownership to 20,660 shares. The acquisition was not an open-market purchase but an internal company transaction.
